Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 1/2 5Phase 2 4Phase 3 2Phase 4 1

Status

Terminated 3Unknown 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Carcinoma, Non-Small-Cell Lung 699Breast Neoplasms 629Neoplasms 582Leukemia, Myeloid, Acute 481Colorectal Neoplasms 455Multiple Myeloma 444Melanoma 424Prostatic Neoplasms 383Neoplasm Metastasis 370Pancreatic Neoplasms 361Recurrence 347Lymphoma 340Ovarian Neoplasms 322Lung Neoplasms 297Lymphoma, Non-Hodgkin 295Leukemia 287Glioblastoma 275Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Stomach Neoplasms 246Leukemia, Lymphocytic, Chronic, B-Cell 235Carcinoma, Hepatocellular 231Squamous Cell Carcinoma of Head and Neck 219Lymphoma, Large B-Cell, Diffuse 217Myelodysplastic Syndromes 212Carcinoma, Renal Cell 210Lymphoma, Follicular 183Head and Neck Neoplasms 172Brain Neoplasms 169Triple Negative Breast Neoplasms 167Lymphoma, Mantle-Cell 167

Interventions

tildrakizumab 1sabizabulin 1pembrolizumab 1enzalutamide 1N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × Metastatic Castration Resistant Prostate Cancer × Clear all
NCT03177187 2024-09-26

ACE

Institute of Cancer Research, United Kingdom

Phase 1/2 Terminated
30 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT04458311 2024-04-25

ACTIon

Institute of Cancer Research, United Kingdom

Phase 1/2 Terminated
13 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03752099 2023-09-26

To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

Veru Inc.

Phase 1/2 Terminated
80 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03658447 2023-07-28

PRINCE

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Completed
37 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT04486937 2020-07-27

mCRPC

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Phase 1/2 Unknown
90 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡